Qure.ai vs Aidoc vs Viz.ai
A side-by-side look at scores, pricing and features — with RECATOOLS' ASEAN-aware verdict for each.
|
|
Aidoc
Always-on clinical AI that triages CT findings — ICH, PE, spinal fract...
Visit
|
Viz.ai
AI-powered care coordination platform with 50+ FDA-cleared algorithms...
Visit
|
|
|---|---|---|---|
| RECATOOLS Score | 8.2 / 10 | 8.2 / 10 | 8.2 / 10 |
| Capability | |||
| Value for money | |||
| Ease of use | |||
| ASEAN readiness | |||
| API quality | |||
| Pricing | Enterprise | Enterprise | Enterprise |
| Free tier | No free tier; enterprise contracts only; trial demos available via sales | No free tier; demo available on request | No free tier; hospital pilots available on request |
| Paid from | Custom enterprise pricing; contact sales for per-scan or site-licence quotes | Custom enterprise pricing; contact sales for per-site or per-volume quotes | Enterprise contracts (estimated six-figure annual fees per health system; volume-based) |
| Has API | ✓ | ✓ | ✓ |
| Open source | ✗ | ✗ | ✗ |
| Free to use | ✗ | ✗ | ✗ |
| Users | 34M+ lives impacted across 4,800+ clinical sites in 105+ countries (as of late 2025) | nearly 2,000 hospitals worldwide; 150+ US health systems; 60M+ cases/year | Nearly 2,000 U.S. hospitals; 60,000+ providers; 230M+ lives covered |
| Founded | 2016 | 2016 | 2016 |
| Maker | Independent (Series D — Lightspeed, 360 ONE Asset, Merck GHI Fund) | Aidoc Medical Ltd. | Dr. Chris Mansi (CEO, neurosurgeon) and Dr. David Golan (CTO, machine learning researcher) |
| Verdict | Qure.ai is one of the most credentialled and widely deployed AI radiology platforms in the world, with a regulatory portfolio (26 FDA-cleared indications, Class IIb CE under EU MDR, CDSCO Class B in India, registrations... |
Aidoc leads the FDA-cleared radiology AI market by clearance count and clinical breadth. Its CARE foundation model — the first to receive FDA clearance for 14 simultaneous abdominal CT indications — represents a genuine... |
Viz.ai is a genuinely differentiated clinical AI platform with the strongest real-world deployment footprint in U.S. acute stroke care. Its De Novo FDA pathway (2018) set the regulatory benchmark for the category, and th... |
| Full review → | Full review → | Full review → |
Comparisons cover up to 4 tools. Scores are RECATOOLS editorial assessments; verify current pricing on each vendor's site.